|
HY-108730-1mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730-10mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730-25mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730-5mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730A-1mg
|
MedChemexpress LLC
|
Avelumab (anti-PD-L1) [CAS 1537032-82-8]
|
|
|
|
|
HY-108730A-10mg
|
MedChemexpress LLC
|
Avelumab (anti-PD-L1) [CAS 1537032-82-8]
|
|
|
|
|
HY-108730A-5mg
|
MedChemexpress LLC
|
Avelumab (anti-PD-L1) [CAS 1537032-82-8]
|
|
|
|
|
HY-108810-1mg
|
MedChemexpress LLC
|
Canakinumab [CAS 914613-48-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-108810-5mg
|
MedChemexpress LLC
|
Canakinumab [CAS 914613-48-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-108852-1mg
|
MedChemexpress LLC
|
Basiliximab [CAS 179045-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-108852-10mg
|
MedChemexpress LLC
|
Basiliximab [CAS 179045-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-108852-5mg
|
MedChemexpress LLC
|
Basiliximab [CAS 179045-86-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-128946-1mg
|
MedChemexpress LLC
|
CL2A-SN-38 [CAS 1279680-68-0]
|
|
Cancer-programmed cell death
|
|
|
HY-128946-10mg
|
MedChemexpress LLC
|
CL2A-SN-38 [CAS 1279680-68-0]
|
|
Cancer-programmed cell death
|
|
|
HY-128946-100mg
|
MedChemexpress LLC
|
CL2A-SN-38 [CAS 1279680-68-0]
|
|
Cancer-programmed cell death
|
|
|
HY-128946-25mg
|
MedChemexpress LLC
|
CL2A-SN-38 [CAS 1279680-68-0]
|
|
Cancer-programmed cell death
|
|
|
HY-128946-5mg
|
MedChemexpress LLC
|
CL2A-SN-38 [CAS 1279680-68-0]
|
|
Cancer-programmed cell death
|
|
|
HY-128946-50mg
|
MedChemexpress LLC
|
CL2A-SN-38 [CAS 1279680-68-0]
|
|
Cancer-programmed cell death
|
|
|
HY-138298A-1mg
|
MedChemexpress LLC
|
Trastuzumab deruxtecan [CAS 1826843-81-5]
|
|
Cancer-Kinase/protease
|
|
|
HY-138298A-5mg
|
MedChemexpress LLC
|
Trastuzumab deruxtecan [CAS 1826843-81-5]
|
|
Cancer-Kinase/protease
|
|
|
HY-141604-1mg
|
MedChemexpress LLC
|
GlembatuMu mab vedotin [CAS 1182215-65-1]
|
|
Cancer-programmed cell death
|
|
|
HY-141604-5mg
|
MedChemexpress LLC
|
GlembatuMu mab vedotin [CAS 1182215-65-1]
|
|
Cancer-programmed cell death
|
|
|
HY-145626-1mg
|
MedChemexpress LLC
|
Ozuriftamab [CAS 2460399-44-2]
|
|
Cancer-Kinase/protease
|
|
|
HY-145626-10mg
|
MedChemexpress LLC
|
Ozuriftamab [CAS 2460399-44-2]
|
|
Cancer-Kinase/protease
|
|
|
HY-145626-5mg
|
MedChemexpress LLC
|
Ozuriftamab [CAS 2460399-44-2]
|
|
Cancer-Kinase/protease
|
|
